- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06042452
Use of Personalized Recommendations, Through Genetic and Lifestyle Data, to Improve Healthcare Staff Wellbeing
Exploring the Utility and Effectiveness of Personalised Insights and Recommendations, Using Genetic and Lifestyle Data, to Improve Employee Health and Wellbeing
With the NHS under increasing pressure and strain, the health and wellbeing of staff is an important area to prioritize, to help reduce staff stress levels and increase retention of staff. This study will look to explore how efficacious personalised insights and recommendations are, based on genetic and lifestyle information, at improving the health and wellbeing of NHS employees. It will also explore how sustainable these recommendations are for long-term change. Recruitment of NHS staff as participants will take place across multiple NHS trusts including Bradford Teaching Hospital NHS Trust and Sandwell and West Birmingham NHS Trust.
Following consent to partake in the trial, participants will be asked to complete a pre-trial questionnaire which will explore health and wellbeing interests and motivations, perceptions of genetic testing, and a baseline measure of mental and physical wellbeing using a standardised and validated questionnaire (5-item World Health Organisation Well-being Index (WHO-5)). This, and all further questionnaires, will be completed online.
Participants will undertake a DNA test provided by FitnessGenes, free of charge. This test will require participants to provide a saliva sample via a spit test. This sample will then be analysed at an ISO-accredited laboratory and results provided back to the participant within 2-3 weeks. While awaiting the results, participants will have access to lifestyle traits calculated using questionnaire data collected when creating a FitnessGenes account.
Once their genetic data is added to a participant's FitnessGenes accounts, they will be asked to spend two weeks exploring this information. A questionnaire will then be completed to reassess participant's wellbeing measures and any changes in their perceptions of DNA testing. At this stage, some semi-structured interviews may be conducted, to those who consent to this, to gain further insight.
A 3-month follow up will be completed to assess whether the platform has had any long-lasting impacts on participants' health and wellbeing.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This will be a 6-week long study to explore the impact of FitnessGenes' platform, with a follow-up after 3 months. NHS staff from multiple NHS trusts will be recruited to partake in the study.
Following consent to partake in the trial, participants will be asked to complete a pre-trial questionnaire which will explore health and wellbeing interests and motivations, alongside taking a baseline measure of mental and physical wellbeing using the 5-item World Health Organization Well-being Index (WHO-5) which has been clinically validated. This, and all further questionnaires, will be completed online.
Participants will undertake a DNA test provided by FitnessGenes, free of charge. This test will require participants to provide a saliva sample via a spit test. This sample will then be analysed at an ISO-accredited laboratory and results provided back to the participant within 2-3 weeks. Test result data is stored in an encrypted format and saliva samples are anonymized using unique barcodes printed on the collection tubes, which do not contain any Personal Information. User identity data (email, name, address, contact info etc.) is kept in a separate database to user personal data (demographic, biometric, lifestyle, genetic etc.). This means all personal data is already kept in an anonymised form.
Once their genetic data is added to a participant's FitnessGenes account, they will be asked to spend a week exploring this upgraded information. A feedback questionnaire will be completed, 3 weeks after they have received their results, to assess participant's experiences of the platform and their results. At this stage, some semi-structured interviews may be conducted, to those who consent to this, to gain further insight.
A 3-month follow up, after the baseline measures were taken, will be completed to assess whether the platform has had any long-lasting impacts on participants' health and wellbeing. This follow up will be completed via a short online questionnaire.
The primary aim of the study is to assess changes in subjects' well-being, as evaluated by the 5-item World Health Organisation Well-being Index (WHO-5).
The investigators will adopt a repeated measures analysis, collecting raw WHO-5 scores from the same subjects at three discrete time points: baseline (i.e. before genetic analysis), 3 weeks after receiving genetic results and at 3 months after baseline. The investigators will also assess the internal consistency of the WHO-5 by performing a Cronbach's alpha test at the three time points.
To assess changes in well-being, raw WHO-5 scores (ranging from 0 to 25) will be multiplied by 4 and transformed into final scores of 0 - 100 for each subject. Descriptive statistics (mean and standard deviation) will be calculated for the 5 individual items of the WHO-5 and the final WHO-5 scores (0-100).
The main dependent variable to be evaluated will be the final WHO-5 Score (ranging from 0-100). The investigators will use repeated measures analysis to assess changes in mean final WHO-5 score across the three different time points.
Briefly, the investigators will assess the distributions of the WHO-5 scores and perform basic tests of normality (including Q-Q plot and performing a Shapiro-Wilkes test) and sphericity/equal variances (Mauchly's test). Depending on the distributions of this data, the investigators will select the appropriate statistical test to assess changes in mean final WHO-5 score.
Assuming normality and sphericity of data and no outliers, the investigators will perform a repeated measures (within-subjects) ANOVA to assess whether the mean final WHO-5 score is statistically significantly different across the three time points. Post-hoc tests will include paired T-tests to make pairwise comparisons in mean final WHO-5 score between the time points, with P-values adjusted using the Bonferroni multiple testing correction method. Depending on the demographic make-up of the subjects, the investigators may include other moderator variables (e.g. gender) to assess for interactions with time point.
If the assumptions behind these parametric tests are violated, a non-parametric alternative (e.g. Friedmans test) will be used to assess changes in mean WHO-5 score. All statistical analysis will be performed using R.
Repeated measures analysis will be used to evaluate the secondary outcomes related to user experience and perceptions of genetic testing.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Geraldine M Campbell, MSc
- Phone Number: 01869255770
- Email: geraldine.campbell@fitnessgenes.com
Study Contact Backup
- Name: Samantha Decombel, PhD
- Phone Number: 01869255770
- Email: sam@fitnessgenes.com
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Health care staff within the NHS (including both clinical and administrative)
- Able to proficiently read English (reports are only produced in English)
Exclusion Criteria:
- Unable to proficiently read English
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Genetic
Participants will have their DNA tested and this data alongside lifestyle data will personalize the information they receive
|
A saliva sample test will be undertaken by all participants in order to analyze their DNA for personalizing their recommendations.
The Global Screening Array (GSA) will be used.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in physical and psychological well-being
Time Frame: Measurements taken at baseline, 3 weeks following receiving personalized recommendations, and at a 3 month follow-up
|
5-Item World Health Organisation Well-being Index (WHO-5). This uses a Likert Scale from 0 ('At no time') to 5 ('All of the time'). A raw score of 0 (lowest well-being) to 25 (highest well-being) is possible on the WHO-5. |
Measurements taken at baseline, 3 weeks following receiving personalized recommendations, and at a 3 month follow-up
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Perceptions of DNA testing
Time Frame: Measurements taken at baseline, 3 weeks following receiving personalized recommendations, and at 3 month follow-up
|
A questionnaire using a scale from Strongly against to Strongly for.
|
Measurements taken at baseline, 3 weeks following receiving personalized recommendations, and at 3 month follow-up
|
How sustainable are the personalized recommendations
Time Frame: Measurements taken at 3 month follow-up
|
A questionnaire that will cover whether recommendations were followed (Yes/No), for how long (1-5 days, 1-2 weeks, 3-4 weeks, 1 month, > 2 months) and how easy participants found implementing the recommendations (scale from Very hard to very easy).
|
Measurements taken at 3 month follow-up
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Stuart Grice, DPhil, FitnessGenes Ltd.
Publications and helpful links
General Publications
- Topp CW, Ostergaard SD, Sondergaard S, Bech P. The WHO-5 Well-Being Index: a systematic review of the literature. Psychother Psychosom. 2015;84(3):167-76. doi: 10.1159/000376585. Epub 2015 Mar 28.
- Ghasemi A, Zahediasl S. Normality tests for statistical analysis: a guide for non-statisticians. Int J Endocrinol Metab. 2012 Spring;10(2):486-9. doi: 10.5812/ijem.3505. Epub 2012 Apr 20.
- Ricciardi W, Boccia S. New challenges of public health: bringing the future of personalised healthcare into focus. Eur J Public Health. 2017 Oct 1;27(suppl_4):36-39. doi: 10.1093/eurpub/ckx164.
- Sauerteig SO, Wijesuriya J, Tuck M, Barham-Brown H. Doctors' health and wellbeing: at the heart of the NHS's mission or still a secondary consideration? Int Rev Psychiatry. 2019 Nov-Dec;31(7-8):548-554. doi: 10.1080/09540261.2019.1586165. Epub 2019 May 14.
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- FG-NHS-Wellbeing
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Well-Being, Psychological
-
University of JyvaskylaAcademy of FinlandCompleted
-
Cardiff UniversityNot yet recruiting
-
University of RochesterCenters for Disease Control and PreventionNot yet recruitingWell-Being, PsychologicalUnited States
-
Samuel Lunenfeld Research Institute, Mount Sinai...Not yet recruitingWell-Being, PsychologicalCanada
-
Cultech LtdCwm Taff Morgannwg University Health Board; Welsh Ambuance services TrustNot yet recruitingWell-Being, Psychological
-
Samuel Lunenfeld Research Institute, Mount Sinai...Not yet recruiting
-
Samuel Lunenfeld Research Institute, Mount Sinai...RecruitingWell-Being, PsychologicalCanada
-
University of Wisconsin, MadisonNot yet recruiting
-
Hong Kong Metropolitan UniversityNot yet recruiting
-
Larena SASNot yet recruitingWell-Being, PsychologicalFrance
Clinical Trials on Genetic
-
Mayo ClinicNational Cancer Institute (NCI)CompletedMalignant Solid Neoplasm | Breast Carcinoma | Digestive System Neoplasm | Skin Carcinoma | Malignant Female Reproductive System Neoplasm | Metastatic Malignant Neoplasm of Unknown Primary | Malignant Head and Neck Neoplasm | Malignant Brain Neoplasm | Malignant Central Nervous System Neoplasm | Malignant... and other conditionsUnited States
-
Ohio State University Comprehensive Cancer CenterActive, not recruitingLynch Syndrome | Relatives | Endometrial Carcinoma | Endometrial AdenocarcinomaUnited States
-
OHSU Knight Cancer InstituteNational Cancer Institute (NCI); Oregon Health and Science UniversityRecruitingMalignant Solid Neoplasm | Lynch Syndrome | Hematopoietic and Lymphoid System Neoplasm | Breast Ductal Carcinoma In Situ | Hereditary Neoplastic Syndrome | BRCA1/2-Associated Hereditary Breast and Ovarian Cancer SyndromeUnited States
-
Augusta UniversityRecruitingOvarian Cancer | Endometrial Cancer | Peritoneal CancerUnited States
-
Thomas Jefferson UniversityProstate Cancer FoundationActive, not recruitingBiochemically Recurrent Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8United States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)TerminatedMetastatic Colon Adenocarcinoma | Metastatic Rectal Adenocarcinoma | Stage III Colon Cancer AJCC v8 | Stage III Rectal Cancer AJCC v8 | Stage IIIA Colon Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Colon Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC v8 | Stage IIIC Colon Cancer AJCC... and other conditionsUnited States
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)CompletedAdvanced Malignant Neoplasm | Locally Advanced Malignant NeoplasmUnited States
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingMalignant Solid Neoplasm | Breast Carcinoma | Digestive System Carcinoma | Head and Neck Carcinoma | Skin Carcinoma | Malignant Female Reproductive System Neoplasm | Malignant Brain Neoplasm | Carcinoma of Unknown Primary | Central Nervous System Carcinoma | Genitourinary System Carcinoma | Malignant Musculoskeletal...United States
-
University of WashingtonNational Cancer Institute (NCI)Active, not recruitingMetastatic Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8United States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditionsUnited States